Combination dual therapy of Empagliflozin and Linagliptin for the management of Type 2 Diabetes
Abstract
Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD) - namely myocardial infarction, heart failure and stroke 1. Despite the efforts and advancements, the impact of T2DM on CVD outcomes remains high and continues to escalate. With the escalation in the severity of hyperglycemia, macrovascular complications increases, thus suggesting an almost linear relation between metabolic disturbances and vascular damage
Downloads
References
Paneni F, Lüscher TF. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. Am J Med. 2017;130(6): S18-S29. doi:10.1016/j.amjmed.2017.04.008
Tan X, Hu J. Traitement combiné par empagliflozin et linagliptin chez les patients atteints de diabète de type 2. Ann Endocrinol (Paris). 2016;77(5):557-562. doi:10.1016/j.ando.2015.11.003
DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384-393. doi:10.2337/dc14-2364
Gita Chawla KKC. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2019;13:2001-2008.
Rosenstock J, Hansen L, Zee P et al. Dual add-on therapy in poorly controlled type 2 diabetes on metformin: a randomized, double-blind trial of saxagliptin + dapagliflozin vs saxagliptin and dapagliflozin alone. diabetes care. 2015;38:376–383.
Cho YK, Kang YM, Lee SE, et al. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018;44(5):393-401. doi:10.1016/j.diabet.2018.01.011
Zinman B, Wanner C, Lachin JM, et al.Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117e2128.
